Article

Successful Outcome of Disseminated Fusarium Infection with Skin Localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia

Parasitologie-Mycologie, Faculté de Médecine, CHRU de Lille, Lille, France.
Journal of Clinical Microbiology (Impact Factor: 4.23). 11/2003; 41(10):4898-900. DOI: 10.1128/JCM.41.10.4898-4900.2003
Source: PubMed

ABSTRACT A disseminated Fusarium oxysporum infection with skin localization was diagnosed in a woman with a relapse of B-acute leukemia during induction chemotherapy. The infection was refractory to amphotericin B-lipid complex alone but responded successfully when voriconazole was added.

Download full-text

Full-text

Available from: Serge Alfandari, Jul 04, 2015
0 Followers
 · 
119 Views
  • Drugs 01/2007; 67(2). DOI:10.2165/00003495-200767020-00009 · 4.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fungal infections caused by Fusarium in the immunocompromised host are highly resistant to all antifungal agents. Fusarium endocarditis is a rare and usually fatal disease. We report an immunocompromised child who survived Fusarium solani endocarditis despite the in vitro resistance of the organism to all available antifungal agents.
    The Pediatric Infectious Disease Journal 12/2004; 23(11):1059-61. DOI:10.1097/01.inf.0000143649.90952.41 · 3.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The persistence of high morbidity and mortality from systemic fungal infections despite the availability of novel antifungals points to the need for effective treatment strategies. Treatment of invasive fungal infections is often hampered by drug toxicity, tolerability, and specificity issues, and added complications often arise due to the lack of diagnostic tests and to treatment complexities. Combination therapy has been suggested as a possible approach to improve treatment outcome. In this article, we undertake a historical review of studies of combination therapy and also focus on recent studies involving newly approved antifungal agents. The limitations surrounding antifungal combinations include nonuniform interpretation criteria, inability to predict the likelihood of clinical success, strain variability, and variations in pharmacodynamic/pharmacokinetic properties of antifungals used in combination. The issue of antagonism between polyenes and azoles is beginning to be addressed, but data regarding other drug combinations are not adequate for us to draw definite conclusions. However, recent data have identified potentially useful combinations. Standardization of assay methods and adoption of common interpretive criteria are essential to avoid discrepancies between different in vitro studies. Larger clinical trials are needed to assess whether combination therapy improves survival and treatment outcome in the most seriously debilitated patients afflicted with life-threatening fungal infections.
    Clinical Microbiology Reviews 02/2005; 18(1):163-94. DOI:10.1128/CMR.18.1.163-194.2005 · 16.00 Impact Factor